Levopropranolol
As of the edition of 20 October 2026, Levopropranolol is a small molecule: stopped in 2023; acts on ADRB1, ADRB2 and ADRB3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Small molecule
- Registered trials
- 10, 4 stopped early
- Disease areas
- Mental health; Skin and connective tissue; Cancer; Chemically induced; Digestive system; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Levopropranolol.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 0 | 0 |
| Phase 2 | 4 | 2 | 0 | 2 |
| Phase 4 | 4 | 2 | 0 | 2 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Lead sponsor of trials | 2007 to now |